샘플 요청 목록

 카트 문의
시장보고서
상품코드
1786753

세계의 흡입제 시장

Inhalable Drugs
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 270 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

흡입제 세계 시장은 2030년까지 946억 달러에 도달

2024년에 695억 달러로 추정되는 흡입제 세계 시장은 분석 기간인 2024-2030년 CAGR 5.3%로 성장하여 2030년에는 946억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 에어로졸은 CAGR4.5%를 나타내고, 분석 기간 종료시에는 515억 달러에 이를 것으로 예측됩니다. 건조 분말 제제 부문의 성장률은 분석 기간에 CAGR 6.5%로 추정됩니다.

미국 시장은 189억 달러로 추정, 중국은 CAGR 8.2%로 성장 예측

미국의 흡입제 시장은 2024년에 189억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 188억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 8.2%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 2.6%와 5.2%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 3.4%를 나타낼 전망입니다.

세계의 흡입제 시장 - 주요 동향과 촉진요인 정리

흡입제 수요 증가의 원동력은?

흡입제 시장은 천식, 만성폐쇄성폐질환(COPD), 낭포성섬유증 등 호흡기 질환의 유병률 증가에 힘입어 큰 폭으로 성장하고 있습니다. 흡입제는 기존 경구약이나 주사제에 비해 빠른 약효 발현, 국소적 약물 전달, 전신 부작용 감소 등 몇 가지 장점이 있습니다. 그 결과, 특히 만성 호흡기 질환에서 환자의 예후를 개선하기 위해 의료 서비스 제공업체와 제약회사는 흡입 요법에 점점 더 많은 노력을 기울이고 있습니다.

호흡기 질환뿐만 아니라 신경질환, 감염질환, 통증 관리 등 흡입제의 적용 범위는 새로운 치료 영역으로 확대되고 있습니다. 흡입제제는 소화관을 우회하여 폐에서 혈류로 직접 약물을 전달할 수 있기 때문에 전신 약물 전달의 대안으로 유망한 약물로 평가받고 있습니다. 또한, 코로나19 사태로 인해 흡입 항바이러스제 및 백신 제제에 대한 연구가 가속화되면서 시장에 대한 관심이 더욱 높아지고 있습니다. 비침습적이고 환자 친화적인 약물 전달 솔루션에 대한 수요 증가는 흡입제 분야의 지속적인 기술 혁신과 시장 확대의 원동력이 될 것으로 예측됩니다.

기술의 발전은 흡입식 약물 전달을 어떻게 변화시킬 것인가?

흡입 약물 전달 시스템의 기술 혁신은 약물의 투여 및 체내 흡수 방식에 혁명을 일으키고 있습니다. 가장 중요한 진전 중 하나는 스마트 흡입기 및 호흡 작동식 장치를 포함한 차세대 흡입 장치의 개발입니다. 이 장치들은 환자의 사용 패턴을 모니터링하고, 순응도를 추적하며, 환자와 의료진 모두에게 실시간으로 피드백을 제공하는 센서와 연결 기능을 갖추고 있습니다. 이러한 기술 혁신은 효과적인 질병 관리를 위해 복약 순응도가 중요한 만성 호흡기 질환 관리에 특히 유용합니다.

또 다른 중요한 돌파구는 약물의 분산과 폐 침착을 개선하는 건식 분말 흡입기(DPI)와 소프트 미스트 흡입기(SMI)의 발전입니다. DPI는 추진제의 필요성을 없애고 생물학적 제제의 안정성을 향상시킵니다. 또한, 나노기술과 지질 기반 약물 전달은 흡입 약물의 생체 이용률을 향상시키고, 펩타이드, 단백질, 유전자 치료제와 같은 복잡한 분자를 효과적으로 전달할 수 있게 해줍니다. 이러한 기술 혁신은 치료 효과를 향상시킬 뿐만 아니라 폐 경로로 전달할 수 있는 약물의 범위를 확장하고 있습니다.

흡입제의 범위를 넓히는 새로운 용도는 무엇인가?

흡입제 시장은 더 이상 호흡기 치료제에 국한되지 않고 새로운 치료 영역으로 빠르게 확대되고 있습니다. 가장 유망한 개발 중 하나는 폐섬유증, 폐감염증, 자가면역질환 등의 치료를 위해 단클론 항체나 유전자 치료제를 포함한 흡입용 생물학적 제제를 사용하는 것입니다. 에어로졸화 생물학적 제제의 발전으로 폐 조직에 표적 전달이 가능해져 전신 노출을 최소화하면서 치료 효과를 극대화할 수 있게 되었습니다.

호흡기 질환 및 비호흡기 질환에 대한 흡입형 백신 개발도 새로운 주요 용도입니다. 코로나19 팬데믹은 주사를 통한 예방접종을 대체할 수 있는 비침습적 흡입 백신에 대한 연구를 가속화했습니다. 흡입 백신은 점막 면역과 전신 면역을 유도할 수 있으며, 호흡기 병원체에 대한 광범위한 방어력을 제공합니다. 또한, 혈액뇌관문을 빠르게 통과하여 치료제를 중추신경계에 직접 전달할 수 있기 때문에 파킨슨병, 편두통, 간질 등 신경질환에 대한 적용이 검토되고 있습니다. 이러한 용도의 확대는 흡입 기반 약물 전달의 새로운 시장 기회를 창출하고 있습니다.

흡입제 시장 전망를 형성하는 주요 성장 촉진요인은 무엇인가?

흡입제 시장의 성장은 호흡기 질환의 유병률 증가, 흡입 기술의 발전, 흡입 기반 치료 범위의 확대 등 여러 요인에 의해 발생합니다. 주요 성장 요인 중 하나는 특히 오염도가 높은 도시 지역의 만성 호흡기 질환 발병률 증가입니다. 장기 흡입 요법을 필요로 하는 환자가 증가함에 따라 제약사들은 신규 흡입제 및 기기 개발에 많은 투자를 하고 있습니다.

시장 확대에 박차를 가하고 있는 또 다른 큰 요인은 흡입용 생물학적 제제와 유전자 치료의 채택이 확대되고 있다는 점입니다. 생물학적 제제 전달에 대한 연구가 진행됨에 따라 폐 질환 및 전신 질환의 치료를 위해 복잡한 고분자를 전달하는 흡입 기술의 활용이 증가하고 있습니다. 또한, 특히 코로나19 팬데믹 이후 흡입형 의약품에 대한 규제 당국의 지원과 신속한 승인으로 인해 시장 성장이 가속화되고 있습니다.

디지털 헬스 및 스마트 흡입 장치의 부상도 시장 전망를 형성하고 있습니다. 헬스케어 시스템이 환자의 원격 모니터링과 개인 맞춤형 의료를 중시하는 가운데, 커넥티드 흡입기와 AI 기반 약물 전달 플랫폼이 인기를 끌고 있습니다. 이러한 기술 혁신은 환자의 순응도와 치료 결과를 개선하고 흡입 기반 치료의 보급을 촉진하고 있습니다.

또한, 환경 친화적이고 추진제 없는 흡입기로의 전환은 시장 역학에 영향을 미치고 있으며, 기업들은 지속 가능한 제형과 환경 친화적 인 제조 공정에 투자하고 있습니다. 정량적 분무식 흡입기(MDI)의 이산화탄소 배출량을 줄여야 한다는 규제 압력이 증가함에 따라 제약회사들은 새로운 저GWP(지구온난화지수) 추진제와 지속 가능한 흡입 기술을 개발하고 있습니다.

부문

약제 클래스별(에어로졸, 드라이 파우더 제제, 스프레이);용도별(호흡기 질환, 비호흡기 질환)

조사 대상 기업 예

  • Amneal Pharmaceuticals Inc.
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici S.p.A.
  • Cipla Inc.
  • Glenmark Pharmaceuticals
  • GSK plc
  • MannKind Corporation
  • Merck & Co., Inc.
  • Mundipharma International
  • Novartis AG
  • Pfizer Inc.
  • Philip Morris International Inc.
  • Pulmatrix, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Vectura Group Ltd.
  • Verona Pharma
  • Viatris Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.14

Global Inhalable Drugs Market to Reach US$94.6 Billion by 2030

The global market for Inhalable Drugs estimated at US$69.5 Billion in the year 2024, is expected to reach US$94.6 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Aerosol, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$51.5 Billion by the end of the analysis period. Growth in the Dry powder formulation segment is estimated at 6.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$18.9 Billion While China is Forecast to Grow at 8.2% CAGR

The Inhalable Drugs market in the U.S. is estimated at US$18.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$18.8 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Inhalable Drugs Market - Key Trends & Drivers Summarized

What Is Driving the Increasing Demand for Inhalable Drugs?

The inhalable drugs market is witnessing substantial growth, driven by the rising prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Inhaled medications offer several advantages over traditional oral and injectable routes, including faster onset of action, localized drug delivery, and reduced systemic side effects. As a result, healthcare providers and pharmaceutical companies are increasingly focusing on inhalation therapies to improve patient outcomes, particularly for chronic respiratory conditions.

Beyond respiratory diseases, the application of inhalable drugs is expanding into new therapeutic areas, including neurological disorders, infectious diseases, and pain management. The ability of inhaled formulations to bypass the gastrointestinal tract and deliver drugs directly into the bloodstream via the lungs has made them a promising alternative for systemic drug delivery. Additionally, the COVID-19 pandemic has accelerated research into inhaled antiviral and vaccine formulations, further fueling interest in the market. The growing demand for non-invasive, patient-friendly drug delivery solutions is expected to drive continued innovation and market expansion in the inhalable drugs sector.

How Are Technological Advancements Transforming Inhalable Drug Delivery?

Technological innovations in inhalable drug delivery systems are revolutionizing the way medications are administered and absorbed in the body. One of the most significant advancements is the development of next-generation inhalation devices, including smart inhalers and breath-actuated devices. These devices are equipped with sensors and connectivity features that monitor patient usage patterns, track adherence, and provide real-time feedback to both patients and healthcare providers. Such innovations are particularly beneficial for managing chronic respiratory conditions, where medication adherence is crucial for effective disease control.

Another key breakthrough is the advancement of dry powder inhalers (DPIs) and soft mist inhalers (SMIs), which improve drug dispersion and pulmonary deposition. DPIs eliminate the need for propellants and offer better stability for biologic drugs, while SMIs provide consistent and fine mist dispersion for better lung penetration. Additionally, nanotechnology and lipid-based drug carriers are enhancing the bioavailability of inhaled drugs, allowing for the effective delivery of complex molecules such as peptides, proteins, and gene therapies. These innovations are not only improving therapeutic efficacy but also expanding the range of drugs that can be delivered via the pulmonary route.

What Are the Emerging Applications Expanding the Scope of Inhalable Drugs?

The inhalable drugs market is no longer limited to respiratory therapies but is rapidly expanding into new and emerging therapeutic areas. One of the most promising developments is the use of inhaled biologics, including monoclonal antibodies and gene therapies, for treating conditions such as pulmonary fibrosis, lung infections, and autoimmune diseases. Advances in aerosolized biologics are enabling targeted delivery to lung tissues, minimizing systemic exposure while maximizing therapeutic benefits.

Another major emerging application is the development of inhalable vaccines for respiratory and non-respiratory diseases. The COVID-19 pandemic has accelerated research into inhalable vaccines, which offer a non-invasive alternative to injectable immunizations. Inhaled vaccines have the potential to induce both mucosal and systemic immunity, providing broader protection against respiratory pathogens. Additionally, inhalable drugs are being explored for neurological disorders, including Parkinson’s disease, migraine, and epilepsy, due to their ability to rapidly cross the blood-brain barrier and deliver therapeutic agents directly to the central nervous system. These expanding applications are unlocking new market opportunities for inhalation-based drug delivery.

What Are the Key Growth Drivers Shaping the Future of the Inhalable Drugs Market?

The growth in the inhalable drugs market is driven by several factors, including the increasing prevalence of respiratory diseases, advancements in inhalation technology, and the expanding scope of inhalation-based therapies. One of the primary growth drivers is the rising incidence of chronic respiratory conditions, particularly in urban areas with high pollution levels. With an increasing number of patients requiring long-term inhalation therapy, pharmaceutical companies are investing heavily in the development of novel inhalable drugs and devices.

Another major factor fueling market expansion is the growing adoption of inhaled biologics and gene therapies. As research into biologic drug delivery advances, inhalation technology is being increasingly utilized to deliver complex macromolecules for the treatment of lung diseases and systemic conditions. Additionally, regulatory support and fast-track approvals for inhalable drug formulations are accelerating market growth, particularly in the wake of the COVID-19 pandemic.

The rise of digital health and smart inhalation devices is also shaping the future of the market. With healthcare systems emphasizing remote patient monitoring and personalized medicine, connected inhalers and AI-driven drug delivery platforms are gaining traction. These innovations are improving patient adherence and therapeutic outcomes, driving further adoption of inhalation-based treatments.

Additionally, the shift toward eco-friendly and propellant-free inhalers is influencing market dynamics, with companies investing in sustainable formulations and greener manufacturing processes. With increasing regulatory pressures to reduce carbon emissions from metered-dose inhalers (MDIs), pharmaceutical firms are developing new low-global-warming-potential (GWP) propellants and sustainable inhalation technologies.

SCOPE OF STUDY:

The report analyzes the Inhalable Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Aerosol, Dry powder formulation, Spray); Application (Respiratory diseases, Non-respiratory disease)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Amneal Pharmaceuticals Inc.
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici S.p.A.
  • Cipla Inc.
  • Glenmark Pharmaceuticals
  • GSK plc
  • MannKind Corporation
  • Merck & Co., Inc.
  • Mundipharma International
  • Novartis AG
  • Pfizer Inc.
  • Philip Morris International Inc.
  • Pulmatrix, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Vectura Group Ltd.
  • Verona Pharma
  • Viatris Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Inhalable Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Respiratory Diseases Such as Asthma and COPD Propels Demand for Inhalation-Based Drug Delivery
    • Growing Preference for Targeted Drug Delivery Systems Enhances Adoption of Pulmonary Therapeutics Across Drug Classes
    • Expansion of Biologics and mRNA Therapeutics Spurs Development of Advanced Dry Powder Inhalers and Nebulizers
    • Rapid Onset and Higher Bioavailability Drive Use of Inhalable Drugs for Acute Pain, Migraine, and Emergency Applications
    • COVID-19 Pandemic Accelerates Interest in Inhalable Antivirals and Vaccine Delivery Formats
    • Increased R&D in Central Nervous System (CNS) and Systemic Therapies Supports Exploration of Inhalable Routes
    • Regulatory Acceptance of New Inhalation Platforms Strengthens Market Entry for Pharma Innovators
    • Advances in Particle Engineering and Nanocarriers Improve Drug Stability and Lung Deposition Efficiency
    • OEM-Pharma Collaborations Drive Innovation in Breath-Actuated and Smart Connected Inhalers
    • Growing Geriatric Population and Pediatric Compliance Issues Support Use of Easy-to-Administer Inhalable Medications
    • Rising Investment in Point-of-Care and At-Home Therapeutic Delivery Devices Enhances Long-Term Market Potential
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Inhalable Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Inhalable Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Inhalable Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Inhalable Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Aerosol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Aerosol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Aerosol by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Dry powder formulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Dry powder formulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Dry powder formulation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Spray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Spray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Spray by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Respiratory diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Respiratory diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Respiratory diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Non-respiratory disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Non-respiratory disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Non-respiratory disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Inhalable Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • JAPAN
    • Inhalable Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • CHINA
    • Inhalable Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • EUROPE
    • Inhalable Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Inhalable Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Inhalable Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Inhalable Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • FRANCE
    • Inhalable Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • GERMANY
    • Inhalable Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Inhalable Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Inhalable Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Inhalable Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Inhalable Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Inhalable Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Inhalable Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • INDIA
    • Inhalable Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Inhalable Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Inhalable Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Inhalable Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Inhalable Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Inhalable Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Inhalable Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Inhalable Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Inhalable Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030
  • AFRICA
    • Inhalable Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Inhalable Drugs by Drug Class - Aerosol, Dry powder formulation and Spray Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Inhalable Drugs by Drug Class - Percentage Breakdown of Value Sales for Aerosol, Dry powder formulation and Spray for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Inhalable Drugs by Application - Respiratory diseases and Non-respiratory disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Inhalable Drugs by Application - Percentage Breakdown of Value Sales for Respiratory diseases and Non-respiratory disease for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제